Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Response to Vaped THC
NCT04340700Phase 3Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dronabinol, sponsored by Massachusetts General Hospital. Planned start Nov 2022; status: withdrawn.
02
Drugs
dronabinol
Beyond the preview
Go deeper on NCT04340700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340700.